Antengene Corporation Ltd
HKEX:6996
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Antengene Corporation Ltd
EPS (Diluted)
Antengene Corporation Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
EPS (Diluted)
¥0
|
CAGR 3-Years
27%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
28%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
25%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
EPS (Diluted)
¥2
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
26%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
EPS (Diluted)
¥9
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's EPS (Diluted)?
EPS (Diluted)
-0.4
CNY
Based on the financial report for Dec 31, 2025, Antengene Corporation Ltd's EPS (Diluted) amounts to -0.4 CNY.
What is Antengene Corporation Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
50%
Over the last year, the EPS (Diluted) growth was 25%. The average annual EPS (Diluted) growth rates for Antengene Corporation Ltd have been 27% over the past three years , 50% over the past five years .
